Treatment Options in Relapsed/Refractory Mantle Cell Lymphoma: Different Factors to Consider
source: pixabay.com

Treatment Options in Relapsed/Refractory Mantle Cell Lymphoma: Different Factors to Consider

In a video posted on OncLive, Dr. Anita Kumar, a medical oncologist, discusses different considerations that must come into play when choosing a treatment for people living with relapsed/refractory mantle…

Continue Reading Treatment Options in Relapsed/Refractory Mantle Cell Lymphoma: Different Factors to Consider
Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval
source: pixabay.com

Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval

According to a story from BioSpace, the biopharmaceutical company Kite announced recently that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency, has released…

Continue Reading Experimental CAR T-Cell Therapy for Mantle Cell Lymphoma May Soon Get EU Approval
This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions
source: pixabay.com

This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions

  A recent article in The American Journal of Managed Care (AJMC) heralds the approval of a third CAR T-cell therapy, called Tecartus. Kite Pharma’s cell-based gene therapy is the first…

Continue Reading This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions
This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions
source: pixabay.com

This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions

  A recent article in The American Journal of Managed Care (AJMC) heralds the approval of a third CAR T-cell therapy, called Tecartus. Kite Pharma’s cell-based gene therapy is the first…

Continue Reading This New Treatment for Mantle Cell Lymphoma has the Potential for Durable Remissions
The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
source: pixabay.com

The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

  Orphan drug designations are granted by the FDA to drugs and biologics that are developed for the treatment of rare diseases.  According to a recent article in Biospace, Oncternal…

Continue Reading The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time

  The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…

Continue Reading FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time